Bavarian Nordic Realigns for Expansion
(Thomson Reuters ONE) -
* Creation of two business divisions; Cancer Vaccines and Infectious Diseases
* Changes in executive management
Kvistgård, Denmark, September 30, 2010 - Bavarian Nordic A/S (OMX: BAVA)
announced today the reorganization of the company's primary business areas into
two divisions; Cancer Vaccines and Infectious Diseases each led by its own
Division President reporting to the President & CEO of the Company.
The establishment of two divisions facilitates a stronger and more effective
management structure and offers a number of benefits to the company, including:
* Optimization of resource management and investments
* Acceleration of development and in-licensing of new products within cancer
and infectious diseases
* Multiple funding options and separate strategic partnership opportunities
Reiner Laus (1)), Executive Vice President and CEO of BN ImmunoTherapeutics,
Inc., Bavarian Nordic's wholly-owned cancer research unit in California, USA has
been appointed Division President Cancer Vaccines. The division's main
short-term strategic objectives are driving PROSTVAC(TM) to the market through
partnership, broadening the portfolio by acquisitions and developing new cancer
targets.
Paul Chaplin (2)), Executive Vice President and Chief Scientific Officer, has
been appointed Division President Infectious Diseases. The division's main
short-term strategic objectives are the continued delivery of IMVAMUNE® under
the contract with the US government, while also securing new IMVAMUNE® orders
and developing new late-stage vaccine candidates for infectious diseases beyond
biodefence, supported by partnerships and/or acquisitions.
In order to provide strong leadership and accountability within the new
structure, the executive management will be consolidated. As a consequence,
Executive Vice President Steen Vangsgaard & Executive Vice President Anders Gram
will be leaving Bavarian Nordic. Morten M. Rasmussen will continue as Senior
Vice President, Legal/IP reporting to Anders Hedegaard. The executive management
team hereafter consists of:
* Anders Hedegaard, President & CEO
* Paul Chaplin, Executive Vice President and Division President Infectious
Diseases
* Reiner Laus, Executive Vice President and Division President Cancer Vaccines
* Ole Larsen, Executive Vice President and Chief Financial Officer
The changes, which will have no immediate impact on the legal structure of the
Group, will take effect as of today.
Bavarian Nordic's President & CEO, Anders Hedegaard commented: "The
establishment of divisions provides the optimum conditions for future growth
within our primary business areas; cancer and infectious diseases, including our
biodefence programmes. The new organizational structure is ideal for generating
short-term results. At the same time we are looking into expanding our
activities in both areas by seeking strategic partnerships, which facilitate
separate collaboration agreements with global pharma companies."
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
1)
Reiner Laus, Executive Vice President and Division President Cancer Vaccines
Dr. Laus is co-founder of BN ImmunoTherapeutics, formed by Bavarian Nordic in
2005 to conduct research and development in the field of recombinant poxviral
vaccines for the immunotherapy of cancer. Since 2008, Dr. Laus has been member
of the executive management of Bavarian Nordic. Before joining the company, Dr.
Laus held the position as Vice President of Research and Development at Dendreon
Corporation, where he worked for 11 years since the inception of the company.
During his tenure at Dendreon, Dr. Laus was a key player in the development of
PROVENGE, the first cancer vaccine to get approved by the FDA. Previously, Dr.
Laus held appointments at the University of Kiel, Germany and at Stanford
University, California. Dr. Laus received his M.D. from the University of Kiel.
2)
Paul Chaplin, Executive Vice President and Division President Infectious
Diseases
Dr. Chaplin has been Chief Scientific Officer at Bavarian Nordic since 2000 and
a member of the executive management team since 2004. Dr. Chaplin has managed
the development of IMVAMUNE® since its conception, together with the other
programmes based on MVA-BN® technology for infectious diseases. Since joining
Bavarian Nordic A/S in 1999, Dr. Chaplin has played a key role in developing the
company's MVA-BN® vaccine technology and is a key inventor on 98 granted patents
and a further 67 pending applications. He is the Principal Investigator of the
company's current RFP-3 contract under Project BioShield, as well as the prior
contracts with the U.S. authorities for the development of IMVAMUNE®, which have
raised more than USD 600 million, including more than USD 1 billion in potential
contract options. Prior joining Bavarian Nordic A/S, Dr. Chaplin worked for
several years both in the UK and Australia developing vaccines against
infectious diseases. He received his PhD from Bristol University, UK.
About Bavarian Nordic
Bavarian Nordic is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's clinical pipeline
targets cancer and infectious diseases, and includes seven development
programmes. Two programmes under preparation for Phase III: PROSTVAC(TM), a
therapeutic vaccine for advanced prostate cancer is being developed under a
collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a
third-generation smallpox vaccine is being developed under a contract with the
US government.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
[HUG#1447675]
201031uk:
http://hugin.info/100065/R/1447675/390271.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 30.09.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 43422
Anzahl Zeichen: 0
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 328 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Realigns for Expansion"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
